Introduction
============

Neutral protamine Hagedorn (NPH) insulin is the most widely used basal insulin worldwide.[@b1-vhrm-5-121] However, NPH insulin may not be the optimal basal insulin due to its significant day-to-day variability, bell-shaped effect curve and estimated 12- to 15-hour duration of action.[@b2-vhrm-5-121],[@b3-vhrm-5-121] In addition, being a suspension of crystals, it needs proper re-suspension, a fact that is often disregarded by patients.[@b4-vhrm-5-121] These characteristics of NPH-insulin render patients more prone to hypoglycemia and usually require the users to be on a twice daily injection schedule to attain 24-hour basal insulin coverage.[@b3-vhrm-5-121] NPH insulin is also associated with weight gain,[@b5-vhrm-5-121] thus further reducing potential compliance.[@b6-vhrm-5-121] These are all factors that are barriers for achieving good glycemic control.

These shortcomings of NPH insulin spurred the development of other basal insulin formulations, of which two are currently marketed: insulin glargine (Lantus^®^; Sanofi Aventis, France); and insulin detemir (Levemir^®^; Novo Nordisk, Denmark). Glargine is synthesized via the substitution of glycine for asparagine at position A21 of the insulin molecule and the addition of two arginine molecules at position B30;[@b2-vhrm-5-121],[@b7-vhrm-5-121] detemir is acylated with a fatty-acid chain (myristic acid) to the lysine at residue B29 of the insulin molecule which mediates albumin binding in the interstitial fluid and plasma.[@b2-vhrm-5-121],[@b8-vhrm-5-121],[@b9-vhrm-5-121] Both come in a clear solution and do not require re-suspension.

Although none of the basal insulin analogs have a completely "flat" pharmacokinetic profile,[@b3-vhrm-5-121] the modulations of the human insulin molecule inherent in detemir and glargine contribute to a "flatter" and more protracted pharmacodynamic profile, with significantly lower within-subject variability, compared with NPH insulin.[@b2-vhrm-5-121],[@b10-vhrm-5-121] In randomized controlled trials (RCT) comparing these insulin analogs with NPH insulin, insulin glargine and detemir demonstrated similar reductions in HbA1c and fasting plasma glucose compared to NPH insulin. Further, the use of these long-acting analogs has also been associated with fewer hypoglycemic episodes, particularly nocturnal hypoglycemia, and has also been associated with less weight gain (especially for detemir) than NPH insulin.[@b5-vhrm-5-121],[@b11-vhrm-5-121],[@b12-vhrm-5-121],[@b13-vhrm-5-121],[@b14-vhrm-5-121]

For these reasons, governmental authorities and/or other payers (eg, insurance companies) in several industrialized countries around the globe (eg, Sweden, Finland, Denmark, UK, US, Australia, Canada, Germany, Spain, France, South Africa) have granted general reimbursement for detemir and glargine in type 1 diabetes mellitus (T1DM), and in some regions their use has exceeded that of NPH insulin. In Norway however, this is currently not the case. The final decision for whether a medicine in Norway will be added to the drug reimbursement formulary lies with the parliament. However, the Norwegian Medicines Agency has the authority to grant reimbursement without consent of the Parliament if the estimated annual increase in cost for national insurance is less than NOK5 million (approximately US\$0.8 million) for the 5 years following the approval of such reimbursement.[@b15-vhrm-5-121]

The Parliament bases their decision on advice from the Norwegian Medicines Agency and the Ministry of Health and Social Affairs who evaluate all applications regarding medical and health economic issues. There are four possible outcome of this process: reimbursement denied (as is the case for orlistat); full reimbursement (as is the case for NPH insulin and all short acting insulin analogs); restricted reimbursement (limited to a certain numbers of prescriptions per year as is currently is the case for the glitazones),[@b15-vhrm-5-121] and reimbursement on a named basis, which means individual patient application for reimbursement and evaluation is on a case by case basis.[@b18-vhrm-5-121] The latter option currently prevails in Norway for the long-acting insulin analogs. However, the likelihood for a patient to obtain this product reimbursed is restricted since the application must come from a specialist in internal medicine or paediatrics. Additionally, it is required that NPH insulin has previously has been tried and that the patient experienced either frequent, or serious nocturnal, hypoglycemic episode(s) or blood glucose variations to an extent that limits optimal glycemic control.[@b17-vhrm-5-121] Patients in Norway with T1DM who receive long-acting insulin analogs by the reimbursement system must therefore be more difficult to manage than patients included in other studies; whether previous RCT results also are applicable to this patient group remains uncertain. We therefore decided to undertake evaluation of the long-term impact on HbA1c in patients with T1DM and at least one documented episode of serious hypoglycemia whose basal insulin prescription was changed from NPH to detemir or glargine. Secondarily, we evaluated the impact of such a change in basal insulin on weight gain, insulin dosage and administration, drug side effects and the frequency of serious hypoglycemic episodes.

Materials and methods
=====================

Inclusion criteria and data collection
--------------------------------------

This retrospective chart review was performed at the diabetic outpatient clinic at Asker and Baerum Hospital (a secondary referral centre in eastern Norway that serves 150,000 residents), where approximately 800 patients with DM receive regular follow-up. Care of T1DM patients is facilitated by a physician or diabetes nurse specialist visit at either 3- or 6-month intervals; these visits include assessment of body weight, HbA1c, lipids, plasma glucose, hemoglobin, creatinine, and insulin regimen (dosage, time and numbers of injections). In addition episodes of serious hypoglycemia (defined as an event requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions)[@b18-vhrm-5-121] are recorded. Patients are referred to an ophthalmologist on a yearly basis and urine albumin excretion rate is evaluated annually. Patients are typically advised to regulate their bolus insulin dosages as needed according to meal composition and influence of any physical activity, alcohol consumption or other factors known to effect insulin needs; the goal is to maintain 2-hour postprandial, fasting and bedtime glucose levels in the range of 4 to 8 mmol/L (72--144 mg/dL). If these goals are not achieved, we recommend that evening, or morning (or both), basal insulin doses are titrated in steps of 2 units (every third day), until respective blood glucose levels are within target range.

Inclusion criteria in this retrospective chart review were: age \> 18 years; T1DM; regular use of insulin glargine or detemir prescription for 12 to 24 months between Dec 2003 and Dec 2007; history of episodes of severe hypoglycemia as per the definition noted above. Exclusion criteria were prior basal insulin use other than NPH-insulin and T2DM.

Subjects eligible for inclusion were identified by authors and personnel at the outpatient clinic. Data from the charts were consistently collected by two persons (authors, OEJ and PJV) and data analysis was conducted by OEJ so as to minimize bias. Results were interpreted after consultation among all authors.

Collection and analysis of blood samples
----------------------------------------

Venous blood samples are drawn between 8 and 10 AM after an overnight fast, within 7 days prior to outpatient clinic visits and are analyzed within 24 hours at the central laboratory of the hospital. Plasma glucose is analysed by utilization of the glucose hexokinase method and HbA1c (upper normal reference value of 6.2%) is analyzed utilizing colorimetric and immunoturbidimetrical methods (Cobas Integra, Roche Diagnostics GmbH, Mannheim, Germany). Serum levels of total cholesterol, high-density lipoprotein (HDL)-cholesterol and triglycerides (TG) are measured enzymatically on a Roche/Hitachi 917 analyzer (Roche Diagnostics GmbH, Mannheim, Germany) whereas low-density lipoprotein (LDL) cholesterol is calculated using the Friedewald formula.

Statistical analysis
--------------------

Based on 2 studies with similar design (a Finnish switch study reporting data for 62 subjects treated for 12 months and a Japanese switch study reporting data for 72 subjects treated for 18 months) we estimated that we in total needed a minimum of 72 subjects treated for a minimum of 12, and a maximum of 24, months with either insulin glargine or insulin detemir[@b19-vhrm-5-121],[@b20-vhrm-5-121] in order to evaluate the long term impact of basal insulin switch according to HbA1c results.

Data analysis was performed using SPSS statistical software version 14.0.1 for Windows (SPSS Inc.). Results for continuous variables are presented as mean and standard deviation unless otherwise stated and categorical variables are presented as counts or proportions (%). Since there was no randomization in this survey we did not perform any between-group comparisons. Comparisons for continuous data were performed with a paired t-test and Pearson bivariate correlation. Comparisons between categorical variables were carried out by chi-squared or Fisher exact test. P-values are 2-sided and considered significant when \<0.05.

Results
=======

In total, 98 patients with DM were found to have used a long-acting insulin analog in the defined period (31.12.2003 to 31.12.2007). Among these, 9 had type 2 DM, 7 were missing initiation data, 1 person used a non-NPH based basal insulin (insulin pump) and 8 had been prescribed insulin analog treatment for a period of less than 12 months. Hence, in total, 73 patients were eligible for analysis, 43 who received a prescription for insulin glargine and 30 for insulin detemir.

The mean follow-up period from initiation of detemir or glargine treatment to last observation was 18 ± 6 (minimum 12, maximum 24) months in both groups. Generally, the patients who had been prescribed these insulins were characterized by relatively long diabetes duration (18 years) and had a relatively high prevalence of micro- and macro-vascular complications ([Table 1](#t1-vhrm-5-121){ref-type="table"}).

[Table 2](#t2-vhrm-5-121){ref-type="table"} shows the insulin regimens that were used at the time of switching to a long-acting insulin analog. Ninety-three percent of subjects used NPH insulin in a twice-daily regimen, 99% had at least one injected dose of bolus insulin whereas 58% injected bolus insulin ≥4 times per day (ie, breakfast, lunch, dinner, evening meal as well as with snacks).

The change to detemir was associated with a statistically significant, −0.4% (95% confidence interval \[CI\] (−0.7, −0.1), p = 0.04), reduction in HbA1c among subjects (baseline 8.3%) and the change to glargine was associated with a −0.3% (95% CI (−0.6, −0.1), p = 0.036) reduction (baseline 8.8%) ([Figure 1a](#f1-vhrm-5-121){ref-type="fig"}). However, the switch did not increase the proportion of patients with HbA1c ≤ 7.0% (ie, 3 and 5 patients before switching to glargine or detemir and, respectively, 4 and 6 after 1 year).

[Table 3](#t3-vhrm-5-121){ref-type="table"} details the half-yearly changes in long-acting and bolus insulin dosages, as well as changes in HbA1c, throughout 24 months. All patients using glargine started with a once-daily regimen (32 \[74%\] in the evening); however, after 24 months, 33% used a twice-daily regimen. Correspondingly, 20% of the detemir users initiated usage with once-daily regimen, but after 24 months, all were following a twice-daily regimen.

Mean insulin detemir and glargine dosages increased, respectively by 4.3 units (U) (95% CI (1.5, 7.1), p = 0.004) and 4.1 U (95% CI (0.1, 8.1), p = 0.045), while the bolus insulin dosage did not ([Figure 1b](#f1-vhrm-5-121){ref-type="fig"}). Weight increased, but not in a statistically significant manner, in both groups ([Figure 1a](#f1-vhrm-5-121){ref-type="fig"}): 0.8 (95% CI (−1.7, 3.3), p = 0.515) kg in the glargine- and 0.3 kg (95% CI (−3.4, 4.0), p = 0.877) in the detemir-treated group.

No correlations were noted between baseline weight and changes in HbA1c, or between baseline weight and changes in weight. However, a significant negative correlation was seen between baseline HbA1c and the reduction in HbA1c for both detemir (r = −0.657, p \< 0.001) and glargine (r = −0.507, p = 0.001). There was also a significant correlation between the increase in insulin dose and reduction in HbA1c for detemir (r = 0.439, p = 0.025), but not for glargine (r = 0.236, p = 0.160).

During the first 12 months, 15 patients experienced a total of 18 serious hypoglycemic episodes, which translates to 0.25 episodes/person year during treatment and such occurrences were similarly distributed among the two groups.

One patient was hospitalized due to ketoacidosis after 6 months of detemir treatment and 2 non-hypoglycemic side effects were observed. One patient developed edema and joint achiness immediately after the initiation of glargine, and 1 developed a local injection site reaction after 21 months of treatment on detemir. None of these events necessitated treatment withdrawal.

Discussion
==========

This retrospective chart review on the use of long-acting insulin analogs over a period of 12 to 24 months in 73 patients with T1DM who had had at least 1 documented episode of serious hypoglycemia, demonstrates that changing from NPH insulin to detemir or glargine improved glycemic control with corresponding decreases in HbA1c levels of −0.3% to 0.4%. The fact that HbA1c levels were not even more dramatically improved may be related to lack of application of a strict treat-to-target algorithm, as in contrast to those in the RCT,[@b13-vhrm-5-121],[@b14-vhrm-5-121] and that the T1DM patients included in this analysis probably are not representative for all patients with T1DM (ie, due to the inclusion criterion), hence their diabetes is possibly more difficult to manage. Predictors for HbA1c improvements were high HbA1c and a positive insulin dosage titration. Interestingly, similar levels of HbA1c reduction was achieved with similar increases in insulin dose for both insulin analogs, which is at variance with some head-to-head RCTs where higher detemir dosages were needed.[@b21-vhrm-5-121],[@b22-vhrm-5-121] There was also the statistically insignificant correlation between HbA1c reduction and weight increase, which is a well-established side effect of NPH-insulin,[@b5-vhrm-5-121] although this finding must be cautiously interpreted.

The impact of these insulin analogs on glycemic control in the current study population is consistent with results from other observational studies documenting a change from NPH to other basal insulins,[@b19-vhrm-5-121],[@b22-vhrm-5-121],[@b23-vhrm-5-121] although conflicting data also exist. One recent publication reports that 62 adolescents treated with glargine for 12 months in Finland had no change in HbA1c (ie, 9.2% both at initiation and 12 months).[@b20-vhrm-5-121] A similar conclusion was recently drawn in a Cochrane review article where no glycemic benefit of long-acting insulin analogs was found compared with intermediate-acting insulin,[@b24-vhrm-5-121] although a beneficial effect on both nocturnal and severe hypoglycemia was noted, with odds ratios of respectively 0.70 (95% CI 0.63--0.79) and 0.73 (95% CI 0.61--0.87). However, it should be noted that this report included studies of relatively short duration, and it is unknown if conclusions would change if studies of longer duration were included.

Serious hypoglycemia was not eliminated after the change from NPH insulin to the detemir or glargine, and still occurred at a prevalence of 0.25/person year of treatment. In a 9- to 12-month long observational study in the UK, the corresponding rate of serious hypoglycemia among patients with T1DM (mean HbA1c 7.8%, diabetes duration 30 years) was 3.2.[@b25-vhrm-5-121] Hence the hypoglycemia rate seen seems low in our survey and is in line with the findings from the Cochrane review,[@b24-vhrm-5-121] but this variance could be related to uncertainties or discrepancies in collection and reporting procedures, in addition to differences in patient characteristics and hypoglycemia occurrence rate as we did not register this rate prior to the switch.

Of interest is also that one third of the patients treated with glargine throughout the 2-year period used it twice daily. This is at variance with the Summary of Product Characteristics (SmPC), stating that glargine should be administrated once daily, while detemir can be administered once or twice daily. This finding is, however, supported by other reports indicating that glargine twice daily is in fact needed in 25% to 33% of adult patients with T1DM.[@b26-vhrm-5-121],[@b27-vhrm-5-121],[@b28-vhrm-5-121]

In conclusion, although the proportion of patients who attained optimal glycemic control (ie, ≤7.0% by HbA1c) was low, serious hypoglycemic episodes were not completely eliminated, the current analyses are limited by being retrospective, are not corrected for the impact of possible confounding factors and were conducted on a limited number of patients, we believe that a 0.3% to 0.4% reduction in HbA1c, and results indicating a relatively low 1-year rate of serious hypoglycemia, are of clinical interest. The improvements noted are important, not only due to the preventive effect on micro- and macrovascular complications,[@b29-vhrm-5-121] but more so in improving quality of life.[@b24-vhrm-5-121],[@b30-vhrm-5-121] On the other hand, this study also underscores the fact that long-acting insulin analogs alone do not solve the problem related to achieving optimal glycemic control and additional tools are needed for the treatment armamentarium for this particular group of patients.

We thank Dr Rolf Whitfield, Dr Harald Smith and the diabetes nurse specialists, Elsa Orvik, Beate Sørgård and Elisabeth Holmen Berg for their contribution in collecting the data.

**Disclosures**

All authors have received lecture honoraria and travel grants from, and/or participated in clinical trials of, Sanofi-Aventis and Novo Nordisk. OEJ was an employee of Novo Nordisk from 2006 to 2007.

![Mean change from initial to last observation for 73 patients with T1DM treated with insulin detemir (n = 30; mean duration of observation, 18 months) and glargine (n = 43; mean duration of observation, 18 months) in **a**) weight (kg) and HbA1c (%) and **b**) bolus- and long-acting insulin dosages. Bars indicate mean and standard error. \*p \< 0.05 from baseline.](vhrm-5-121f1){#f1-vhrm-5-121}

###### 

Background data and glycemic and lipid parameters (before changing basal insulin analogs) for 73 patients with T1DM treated with a long-acting insulin analog (detemir or glargine) for 12 to 24 months

                                                                      **All (n = 73)**      **Detemir (n = 30)**   **Glargine (n = 43)**
  -------------------------------------------------- ---------------- --------------------- ---------------------- -----------------------
  Background                                                                                                       
    Age (year)                                                        48 (17,83)            52 (23,78)             46 (17,83)
    Gender (male/female)                                              42 (58%)/31 (42%)     16 (53%)/14 (47%)      26 (61%)/17 (39%)
    Diabetes duration (year)                                          19 (1,54)             26 (1,54)              14 (2, 45)
    Weight (kg)                                                       78.3 (49.4, 131.0)    81.4 (51.0, 131.0)     76.4 (49.4, 105.0)
    BMI (kg/m^2^)                                                     25.9 (16.9, 42.8)     27.2 (22.9, 42.8)      25.3 (16.9, 33.0)
  Microvascular complications                                                                                      
    Retinopathy                                                       25 (34%)              16 (53%)               9 (21%)
    Neuropathy                                                        16 (22%)              8 (27%)                8 (19%)
    Albuminuria (micro/macro)                                         24 (33%)              11 (37%)               13 (30%)
  Other complications                                                                                              
    Cerebro, peripheral or coronary artery disease                    27 (37%)              15 (50%)               12 (28%)
    Thyroid disorder                                                  9 (12%)               3 (10%)                6 (14%)
  Medications other than insulin                                                                                   
    Statins                                                           32 (44%)              18 (60%)               14 (33%)
    Platelet inhibitor                                                17 (23%)              9 (30%)                8 (19%)
    ACE-inhibitor/AT-II receptor blocker                              31 (44%)              17 (57%)               14 (33%)
    Diuretics                                                         13 (18%)              6 (20%)                7 (16%)
  Laboratory parameters                                                                                            
    HbA1c (%)                                                         8.6 (5.7, 11.7)       8.3 (5.7, 11.3)        8.8 (6.8, 11.7)
    Glucose                                          mmol/L           11.6 (2.4, 24.0)      10.7 (2.4, 18.5)       12.2 (3.2, 24.0)
                                                     mg/dL            208.8 (43.2, 432.0)   192.6 (43.2, 333.0)    219.6 (57.6, 432.0)
    Total cholesterol                                mmol/L           4.8 (3.0, 7.6)        4.9 (3.6, 6.3)         4.8 (3.0, 7.6)
  mg/dL                                              186 (116, 294)   189 (139, 244)        186 (116, 294)         
    LDL-cholesterol                                  mmol/L           2.6 (1.1, 4.4)        2.5 (1.2, 3.5)         2.6 (1.1, 4.4)
  mg/dL                                              101 (43, 170)    97 (46, 135)          101 (43, 170)          
    HDL-cholesterol                                  mmol/L           1.7 (0.9, 2.9)        1.9 (1.2, 2.9)         1.6 (0.9, 2.8)
  mg/dL                                              66 (35, 112)     73 (46, 112)          62 (35, 112)           
  Triglycerides                                      mmol/L           1.1 (0.4, 2.7)        0.9 (0.4, 2.1)         1.2 (0.4, 2.7)
  mg/dL                                              97 (35, 239)     78 (35, 186)          106 (35, 239)          
  Hemoglobin (g/dL)                                                   14.1 (10.8, 16.3)     14.2 (11.0, 16.3)      14.0 (10.8, 16.2)
  Creatinine (μmol/L)                                                 76 (41, 153)          75 (44, 118)           77 (41, 153)

**Note:** Data given as mean (min., max.) for numerical and n (%) for categorical parameters.

**Abbreviations:** ACE, angiotensin converting enzyme; AT-II, angiotensin II; HbA1c, hemoglobin A1c; LDL, low density lipoprotein; HDL, high density lipoprotein.

###### 

Details of insulin treatment regimens prior to changing basal insulin from NPH to detemir or glargine

                               **All (n = 73)**   **Detemir (n = 30)**   **Glargine (n = 43)**
  ---------------------------- ------------------ ---------------------- -----------------------
  Basal insulin (NPH)                                                    
  Daily insulin dosage (U)     30 (10, 80)        28 (10, 74)            31 (12, 80)
    Number of injections (n)                                             
      1                        5 (7%)             3 (10%)                2 (5%)
      2                        68 (93%)           27 (90%)               41 (95%)
  Bolus insulin                                                          
    Human insulin (n)          7 (10%)            2 (7%)                 5 (12%)
    Insulin analog (n)         65 (89%)           28 (93%)               37 (86%)
    No bolus insulin (n)       1 (1%)             0 (0%)                 1 (2%)
    Daily insulin dosage (U)   24 (0, 80)         25 (10, 80)            24 (0, 72)
    Number of injections (n)                                             
      0                        1 (1%)             0 (0%)                 1 (2%)
      1                        4 (6%)             1 (3,3%)               3 (7%)
      2                        6 (8%)             2 (6,7%)               4 (9%)
      3                        20 (27%)           6 (20%)                14 (33%)
      ≥4                       42 (58%)           21 (70%)               21 (49%)

**Note:** Data given as mean (min., max.) for numerical and n (%) for categorical parameters.

**Abbreviation:** U, international unit.

###### 

Half-yearly changes in insulin dosage, HbA1c and proportion of T1DM patients receiving insulin once daily, over 24 months of treatment with either insulin detemir or glargine

              **Detemir**   **Glargine**                                                                                                                                                                                                                              
  ----------- ------------- ---------------------------------------------------------- ----- ---------------- --------------------------------------------------------------- ---- --------------------------------------------------------- ------ ----------------- ---------------------------------------------------------------
  Base-line   30            25 (10,78)                                                 20%   25 (10,80)       8.3% (5.7, 11.3)                                                43   26 (11,60)                                                100%   24 (0,72)         8.9% (6.8, 12.2)
  6 months    26            3[\*](#tfn6-vhrm-5-121){ref-type="table-fn"} (0.1, 6.6)    6%    −1 (−4.0, 3.6)   −0.4%[\*](#tfn6-vhrm-5-121){ref-type="table-fn"} (−0.8, −0.1)   35   3[\*](#tfn6-vhrm-5-121){ref-type="table-fn"} (0.4, 5.3)   87%    2 (−4.9, 8.0)     −0.1% (−0.4, 0.2)
  12 months   30            3[\*](#tfn6-vhrm-5-121){ref-type="table-fn"} (1.4, 5.5)    5%    −2 (−4.4, 1.6)   −0.5%[\*](#tfn6-vhrm-5-121){ref-type="table-fn"} (−0.8, −0.1)   43   4 (−0.1, 7.3)                                             74%    3 (−5.3, 11.0)    −0.2% (−0.5, 0.1)
  18 months   11            3 (−3.5, 8.7)                                              10%   −1 (−8.7, 6.5)   −0.3% (−0.9, 0.2)                                               21   6 (−0.1, 12.9)                                            72%    −2 (−9.7, 5.7)    −0.7%[\*](#tfn6-vhrm-5-121){ref-type="table-fn"} (−1.3, −0.2)
  24 months   15            6[\*](#tfn6-vhrm-5-121){ref-type="table-fn"} (1.6, 10.1)   0%    2 (−1.9, 5.6)    −0.6% (−1.2, 0.1)                                               18   7 (−1.3, 16.2)                                            67%    −2 (−10.4, 5.7)   −0.6%[\*](#tfn6-vhrm-5-121){ref-type="table-fn"} (−1.2, −0.1)

**Notes:** Data given as mean (min., max.) for insulin initiation dosage and baseline data whereas changes are given as mean (95% confidence interval).

p \< 0.05 from 1st observation (within-group comparison).

**Abbreviation:** U, international unit.
